Evidence map›Paper›PMID 42485310›Full record

ArticlePLOS global public health2026

Implementation of differentiated service delivery strategies for patients with tuberculosis in Haiti during a severe humanitarian crisis, January-August 2021.

Stalz Charles Vilbrun, Christina Braccio, Gerry Marcel Augustin, Kesner François, Milo Richard, Patrice Joseph, Jennifer B Harris, Macarthur Charles

Abstract read
In one paragraph

Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stalz Charles VilbrunLes Centres GHESKIO, Port-au-Prince, Haiti.ORCID https://orcid.org/0009-0002-9482-1725
Christina BraccioDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-9612-0087
Gerry Marcel AugustinDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Port-au-Prince, Haiti.ORCID https://orcid.org/0000-0002-7953-2119
Kesner FrançoisNational HIV Program, Ministry of Health, Port-au-Prince, Haiti.
Milo RichardNational Tuberculosis Program, Ministry of Health, Port-au-Prince, Haiti.
Patrice JosephLes Centres GHESKIO, Port-au-Prince, Haiti.
Jennifer B HarrisDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0003-4105-8447
Macarthur CharlesDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-3822-5737

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global efforts to control tuberculosis (TB) faced significant challenges during the COVID-19 pandemic, particularly in Haiti, where it coincided with a severe humanitarian crisis. To minimize facility visits for patients, a differentiated service delivery (DSD) model with multi-month dispensing of TB drugs was implemented at two high-volume health facilities in Port-au-Prince, Haiti. All patients aged 18 years and older who initiated drug-susceptible TB treatment from January 1 to August 31, 2022 were included in the prospective cohort. Clinicians first identified clinically stable patients who met criteria for DSD eligibility and offered them enrollment in the DSD model. Those deemed unsuitable for DSD or declined DSD were treated under the standard of care (SOC) model. DSD patients received an initial 2-month supply of medication followed by either a 4-month supply or two additional 2-month supplies. They also received remote follow-up via mobile communication within 24-48 hours of treatment initiation, biweekly during the first two months, and monthly during the last four months. Under SOC, patients came to the facility for clinical review and drug dispensation every 2-4 weeks during the first two months, and monthly during the last four months. Robust Poisson regression was used to analyze the relationship between treatment success and cohort type. During the project period, a total of 551 patients initiated TB treatment: 151 in the DSD model and 400 under SOC. Thirty-nine percent were female; median age was 33 years; and 25% were HIV-positive. Treatment success (defined as those who were cured or completed treatment) was significantly higher in the DSD group at (140/151; 93%), compared to 312/400 (78%) in the SOC group (adjusted risk ratio [aRR]: 1.10, p = 0.02): however, there was no significant difference after excluding patients who were lost-to-follow-up (aRR: 1.00; p = 0.85). This project demonstrates that a DSD model can achieve high TB treatment success rates, even amid challenging circumstances like the COVID-19 pandemic and socio-political unrest. Adapting healthcare systems through innovative service delivery methods is essential to effectively meet patient needs during global health crises.

Identifiers

PMID42485310
PMCPMC13390852

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.